Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Hashimoto

Showing results (1-10 of 861) with videos related to

Pageof 87
Sort By:
Psychiatry and Clinical Neurosciences|June 20, 2019
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspectiveKenji Hashimoto
Science (New York, N.Y.)|May 8, 2025
Extending ketamine's antidepressant effectsKenji Hashimoto
The Open Medicinal Chemistry Journal|January 22, 2011
Glycine transport inhibitors for the treatment of schizophreniaKenji Hashimoto
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 6, 2010
The role of glutamate on the action of antidepressantsKenji Hashimoto
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 4, 2010
Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatmentKenji Hashimoto
CNS & Neurological Disorders Drug Targets|August 26, 2009
Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?Kenji Hashimoto
Expert Opinion on Therapeutic Targets|August 19, 2016
Soluble epoxide hydrolase: a new therapeutic target for depressionKenji Hashimoto
Brain, Behavior, and Immunity|August 9, 2019
Understanding the link between maternal infections and neurodevelopmental disorders in offspring: The role of abnormalities in metabolism of polyunsaturated fatty acidsKenji Hashimoto
JAMA Neurology|May 14, 2014
Serum brain-derived neurotrophic factor as a predictor of incident dementiaKenji Hashimoto
Expert Review of Neurotherapeutics|August 1, 2013
Therapeutic implications for NMDA receptors in mood disordersKenji Hashimoto
Pageof 87

Showing results (1-10 of 861) with videos related to

Sort By:
Pageof 87
Psychiatry and Clinical Neurosciences|June 20, 2019
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspectiveKenji Hashimoto
Science (New York, N.Y.)|May 8, 2025
Extending ketamine's antidepressant effectsKenji Hashimoto
The Open Medicinal Chemistry Journal|January 22, 2011
Glycine transport inhibitors for the treatment of schizophreniaKenji Hashimoto
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 6, 2010
The role of glutamate on the action of antidepressantsKenji Hashimoto
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 4, 2010
Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatmentKenji Hashimoto
CNS & Neurological Disorders Drug Targets|August 26, 2009
Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?Kenji Hashimoto
Expert Opinion on Therapeutic Targets|August 19, 2016
Soluble epoxide hydrolase: a new therapeutic target for depressionKenji Hashimoto
Brain, Behavior, and Immunity|August 9, 2019
Understanding the link between maternal infections and neurodevelopmental disorders in offspring: The role of abnormalities in metabolism of polyunsaturated fatty acidsKenji Hashimoto
JAMA Neurology|May 14, 2014
Serum brain-derived neurotrophic factor as a predictor of incident dementiaKenji Hashimoto
Expert Review of Neurotherapeutics|August 1, 2013
Therapeutic implications for NMDA receptors in mood disordersKenji Hashimoto
Pageof 87